sorafenib

sorafenib

美 　英

• 网络索拉非尼；索拉菲尼；多吉美

例句

Hepatology Digest: The last thing I would like to ask you about is sorafenib .

国际肝病：最后我想问的是索拉非尼。

We are currently doing a multi-centre trial looking to see if the addition of sorafenib in adjuvant therapy will be beneficial.

目前，我们正在进行一项多中心临床试验，研究在辅助治疗方案中添加索拉非尼是否有效。

For those patients with advanced HCC, who have had surgical resection, with the surgery impact the safety and efficacy of sorafenib ?

对于已进行了手术的晚期肝癌患者，手术会影响索拉非尼的安全性和疗效吗？

In the latter scenario, sorafenib should also constitute the control arm of these trials.

在近来的方案中，索拉菲尼将成为这些实验中的控制臂。

Sorafenib is currently approved in the United States and other countries for treatment of advanced renal cell carcinoma.

当前索拉非尼在美国和其他国家被批准用来治疗晚期肾细胞癌。

The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.

目前还没有2期或3期试验对索拉非尼与多柔比星联用治疗晚期HCC患者进行评价。

Investigators and cooperative groups are currently evaluating sorafenib in various breast cancer treatment settings, according to Bayer.

据拜耳消息，研究人员和投资方目前正在对索拉非尼应用于各种乳腺癌治疗情况进行评测。

Consequently, sorafenib will become the standard of care in advanced cases, and the control arm for future trials.

同时，索拉菲尼将会是早期病例的标准治疗方法和未来试验的对照药。

The study was stopped prematurely when a planned interim analysis showed sorafenib's significant superiority over placebo.

根据计划，当中期分析显示索拉非尼的效果明显优于安慰剂时，研究会过早的中止。

Treatment duration was a median of 23 weeks in the sorafenib group and 19 weeks in the placebo group.

治疗时间中位数在索拉非尼组为23周，在安慰剂组为19周。

OBJECTIVE To synthesize sorafenib a new anti-tumor drug.

目的合成抗肿瘤新药索拉非尼。

Hepatology Digest: There is obviously a lot of talk about sorafenib at this year's meeting.

国际肝病：在今年的会议上有很多关于索拉菲尼的研究报道。

Median overall survival was 46 weeks in the sorafenib group and 34 weeks in the placebo group (HR 0. 69, P =. 00058).

在索拉非尼组的中位数总生存率为46周，而在安慰剂组为34周（HR0.69；P=.00058）。

Hepatology Digest: Do you think that with more and more clinical trials regarding sorafenib, do you think it will update the guidelines?

《国际肝病》：随着索拉菲尼临床试验数据的不断丰富，您认为索拉菲尼将会改变当前肝癌的诊疗指南吗？